North America
Tags: Canada, Life SciencesBy Richard Y. Cheung, Ph.D., Toronto, Fasken Martineau DuMoulin
Due to concerns about the growing percentage of the health care budget allotted to drug spending in Canada and the relative drug prices in Canada compared to other developed countries, the Canadian government is proposing changes to the way in which prices for patented drugs are regulated …
Read or download the full article below.
Latest Updates
Who’s Afraid of AI? - Tech Tales with Paul Haswell
Join Paul Haswell, a partner at K&L Gates in Hong Kong, as he explores the transformative impact of technology on the legal profession in his new column for IHC Magazine. Paul offers insights into the challenges and opportunities for ...
Related Articles
Who’s Afraid of AI? - Tech Tales with Paul Haswell
Join Paul Haswell, a partner at K&L Gates in Hong Kong, as he explores the transformative impact of technology on the legal profession in his new column for IHC Magazine. Paul offers insights into the challenges and opportunities for ...
Related Articles by Jurisdiction
Merger control and foreign investment review in Canada
Fasken Martineau DuMoulin’s Huy Do and Jack Yu1 write that acquisitions of, or investments in, Canadian businesses can give rise to merger control and foreign investment reviews. ...
Deconstructing the new Construction Act
The amendments are intended to enhance the efficiency and competitiveness of construction industry stakeholders.
Canada: New Strategic Plan for the Patented Medicines Prices Review Board
The Strategic Plan comprises a fresh vision, a revised mission statement and four new strategic objectives ...
Latest Articles
